Logo
x

Search

Subscribe Now

urothelial cancer

Advancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots

Advancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots

  • September 4, 2024
Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial Carcinoma

Astellas and Seagen's Padcev (enfortumab vedotin) Receive MHLW's Approval for the Treatment of Radically Unresectable Urothelial C...

  • September 27, 2021
Astellas and Seagen's Padcev (enfortumab vedotin-ejfv) Receive the US FDA's Full Approval and Expands Indication for Patients with Locally Advanced or Metastatic Urothelial Cancer

Astellas and Seagen's Padcev (enfortumab vedotin-ejfv) Receive the US FDA's Full Approval and Expands Indication for Patients with...

  • July 12, 2021
Astellas and Seagen Report the US FDA's Acceptance of Two sBLA for Padcev (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer

Astellas and Seagen Report the US FDA's Acceptance of Two sBLA for Padcev (enfortumab vedotin) in Locally Advanced or Metastatic U...

  • April 20, 2021
Astellas and Seagen Report EMA's Acceptance of MAA for Enfortumab Vedotin to Treat Locally Advanced or Metastatic Urothelial Cancer

Astellas and Seagen Report EMA's Acceptance of MAA for Enfortumab Vedotin to Treat Locally Advanced or Metastatic Urothelial Cance...

  • March 26, 2021
Astellas Reports NDA Submission of Enfortumab Vedotin to the MHLW for Locally Advanced or Metastatic Urothelial Cancer in Japan

Astellas Reports NDA Submission of Enfortumab Vedotin to the MHLW for Locally Advanced or Metastatic Urothelial Cancer in Japan

  • March 12, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.